Clinical trial · Observational
Imiquimod and Actinic Keratoses: an Observational Study
Actinic Keratoses and 5% Topical Imiquimod: Lessons to Learn From a Prospective Non-Interventional Study by 93 Office-based Dermatologists
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Objective: To show how dermatologists treat actinic keratoses with imiquimod 5% cream in their daily clinical routine. Design: Prospective, non-interventional, observational, multicenter clinical study. Setting: Offices of 93 non hospital based Austrian dermatologists. Participants: Inclusion of the 463 patients into the study was solely based on the treatment decision of the dermatologist and the patients will. Interventions: No specific interventions except suggested time points of visits with pre-defined documentation forms. The therapy of actinic keratoses followed the imiquimod label (3x/week for 4 weeks, 4 therapy free weeks, another 3x/week for 4 weeks, when needed) Main outcome measure: Information about the typical imiquimod patient, therapeutic course, treatment decisions, safety and satisfaction of patients/dermatologists.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Actinic Keratosis | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- actinic keratosis patients
- description
- patients who see their non-hospital based dermatologist, because of multiple actinic keratoses and who are then routinely treated with topical 5% Imiquimod
Primary outcomes (1)
- measure
- Management of the actic keratosis patient routinely treated with Imiquimod by non-hospital based dermatologists
- timeFrame
- 12 weeks
- description
- Information about the typical imiquimod patient, therapeutic course, treatment decisions and satisfaction of patients/dermatologists.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * no study specific, just following the label of imiquimod Exclusion Criteria: * no study specific, just following the label of Imiquimod
References
Publications (1)
- DERIVEDStrohal R, Kerl H, Schuster L. Treatment of actinic keratoses with 5% topical imiquimod: a multicenter prospective observational study from 93 Austrian office-based dermatologists. J Drugs Dermatol. 2012 May;11(5):574-8. PMID 22527424